Availability of a third dose of any of the current COVID-19 vaccines would require either amending the US Food and Drug Administration (FDA) emergency use authorization or granting full FDA approval status to the vaccine. The possibility of a third-dose authorization or approval has not been wi...
COMIRNATY (COVID-19 Vaccine, mRNA) and the Pfizer-BioNTech COVID-19 Vaccine intended for individuals 12 years of age and older should not be used for individuals 6 months through 11 years of age because of the potential for vaccine administration errors, including dosing errors.3 SUMMARY OF...
■ For the latest updates on vaccine availability and other COVID-19-related updates, please visit hf.org/staywell. This page will be updated regularly when new information is available. Vaccinations are also being offered through the Brevard County Department of Health. For mo...
COMIRNATY, our COVID-19 vaccine contributed $1.4 billion in revenue. Our COVID-19 products were not the only drivers during the quarter. Our non-COVID products also exhibited robust performance with revenues of $13.6 billion, reflecting 14% operational year-over-year growth. This performance ...
Expanding vaccine availability to roughly 28 million more U.S. children was seen as another milestone in the fight against the virus and comes amid an alarming rise in serious infections in youngsters because of the extra-contagious delta variant. In the United States, COVID-19 has k...
(COVID-19 Vaccine, mRNA, 2023-2024 Formula), the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula), Comirnaty Original/Omicron BA.1, Comirnaty Original/Omicron BA.4/BA.5 and Comirnaty XBB.1.5. “Comirnaty” includes direct sales and alliance revenues related to sa...
Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “We are encouraged by the strong performance of Pfizer’s non-COVID products in the third quarter of 2023, including significant contributions from new launches and robust year-over-year growth for several key in-line brands. We...
doi:10.1001/jamainternmed.2022.0761 Despite the availability of safe and effective COVID-19 vaccines, 25% of American adults remained partially vaccinated or unvaccinated against COVID-19 at the beginning of 2022.1 Lack of a formally approved COVID-19 vaccine was a common reason given for non...
“Honestly, it was availability,” Martinez-Uribe said of the choice. “By luck, I was able to find one pharmacy in our entire 30-mile area here in Newnan that had the molnupiravir.” And that’s not just the case in rural Georgia. Plaxovid’s scarcity is a story heard across ...
Pfizer is asking the U.S. government to allow use of its COVID-19 vaccine in children ages 5 to 11. If regulators agree, shots could begin within a matter of weeks.